Global cardiometabolic risk profile in patients with hypertension: Results from the Turkish arm of the pan-European GOOD survey

Turk Kardiyoloji Dernegi Arsivi

Volumn 38, Issue 5, 2010, Pages 313-320

  Kabakci, Giray ^a   Aydin, Mustafa ^b   Demir, Ibrahim ^c   Kirma, Cevat ^d   Özerkan, Filiz ^e  

^a HACETTEPE UNIVERSITY   (Turkey)

^b Zonguldak Karaelmas Universitesi Tip Fakultesi   (Turkey)

^c AKDENIZ UNIVERSITY   (Turkey)

^d Kartal Lutfi Kirdar Education and Research Hospital   (Turkey)

^e EGE UNIVERSITY   (Turkey)

Author keywords

Diabetes mellitus, type 2; Dyslipidemias; Hypertension epidemiology therapy; Metabolic syndrome X; Prevalence; Turkey epidemiology

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA GLUCOSIDASE INHIBITOR; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOOP DIURETIC AGENT; NITRATE; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; EUROPE; FEMALE; GOOD SURVEY; HEALTH SURVEY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTPATIENT; PREVALENCE; RISK FACTOR; SEDENTARY LIFESTYLE; SYSTOLIC BLOOD PRESSURE; TURKEY (REPUBLIC);

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; RISK FACTORS; TURKEY;

EID: 79953274871     PISSN: 10165169     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Lawes CM, Vander Hoorn S, Law MR, Elliott P, MacMahon S, Rodgers A. Blood pressure and the global burden of disease 2000. Part II: estimates of attributable burden. J Hypertens 2006;24:423-30.
2. Franco OH, Peeters A, Bonneux L, de Laet C. Blood pressure in adulthood and life expectancy with cardiovascular disease in men and women: life course analysis. Hypertension 2005;46:280-6. (Pubitemid 41099158)
3. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23. (Pubitemid 40138015)
4. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87. (Pubitemid 46924065)
5. American Heart Association. Heart disease and stroke statistics-2008 update. Dallas, TX: American Heart Association; 2008.
6. Ma J, Stafford RS. Screening, treatment, and control of hypertension in US private physician offices, 2003- 2004. Hypertension 2008;51:1275-81.
7. Hanefeld M, Koehler C, Gallo S, Benke I, Ott P. Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study. Cardiovasc Diabetol 2007;6:13.
8. Volpe M, Tocci G, Trimarco B, Rosei EA, Borghi C, Ambrosioni E, et al. Blood pressure control in Italy: results of recent surveys on hypertension. J Hypertens 2007;25:1491-8. (Pubitemid 46918838)
9. MacDonald TM, Morant SV, Mozaffari E. Treatment patterns of hypertension and dyslipidaemia in hypertensive patients at higher and lower risk of cardiovascular disease in primary care in the United Kingdom. J Hum Hypertens 2007;21:925-33. (Pubitemid 350167097)
10. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991;83:356-62.
11. Sytkowski PA, D'Agostino RB, Belanger AJ, Kannel WB. Secular trends in long-term sustained hypertension, long-term treatment, and cardiovascular mortality. The Framingham Heart Study 1950 to 1990. Circulation 1996;93:697-703.
12. Murray CJ, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge (MA): Harvard School of Public Health; 1996.
13. Kjeldsen SE, Naditch-Brule L, Perlini S, Zidek W, Farsang C. Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with hypertension disease survey. J Hypertens 2008;26:2064-70.
14. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52. (Pubitemid 41532612)
15. Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med 2007;167:141-7. (Pubitemid 46151611)
16. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43:10-7.
17. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.
18. Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M, Kader B, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998;339:1957-63. (Pubitemid 29024127)
19. Oliveria SA, Lapuerta P, McCarthy BD, L'Italien GJ, Berlowitz DR, Asch SM. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002;162:413-20. (Pubitemid 34150642)
20. Hyman DJ, Pavlik VN. Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. Arch Intern Med 2000;160:2281-6.
21. Bramlage P, Thoenes M, Kirch W, Lenfant C. Clinical practice and recent recommendations in hypertension management-reporting a gap in a global survey of 1259 primary care physicians in 17 countries. Curr Med Res Opin 2007;23:783-91. (Pubitemid 46631482)
22. Can G, Schwandt P, Onat A, Hergenç G, Haas GM. Body fat, dyslipidemia, blood pressure and the effects of smoking in Germans and Turks. Turk J Med Sci 2009;39:579-89.
23. Onat A, Uǧur M, Hergenç G, Can G, Ordu S, Dursunoǧlu D. Lifestyle and metabolic determinants of incident hypertension, with special reference to cigarette smoking: a longitudinal population-based study. Am J Hypertens 2009;22:156-62.
24. Onat A, Hergenç G, Sari I, Türkmen S, Can G, Sansoy V. Dyslipidemic hypertension: distinctive features and cardiovascular risk in a prospective population-based study. Am J Hypertens 2005;18:409-16. (Pubitemid 40416712)
25. Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000;356:1955-64.
26. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38.